Dr. Vince Clinical Research (DVCR), has launched a new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas.
 
The custom-built, green-inspired research complex was intentionally designed and engineered—with significant investments in infrastructure, research-changing technologies, employee wellness and excellence and environmental sustainability—to be the premier destination in the country for Phase I clinical studies.

Dedicated to Phase I Clinical Trials

“Our vision was to create the top clinical pharmacology unit in the U.S. that enables delivering faster and cleaner data to our biopharmaceutical clients,” said Brad Vince, D.O., a 20-year industry veteran and founder, CEO and medical director. “To accomplish our goals and transform standard industry practices, we built one of the most innovative and technologically advanced Phase I sites ever.”
 
The company leveraged a robust team of engineers and consultants to plan and construct the new facility and help ensure seamless deployment of the latest technologies for both the physical infrastructure of the 90-bed center and company operations and processes. These key technologies enable the company to deliver higher quality data more efficiently than current industry standards, including:
 
eSource/EDC platform with equipment integration for automated data upload
Automated building and inventory management systems
Cloud-based environmental monitoring of pharmacy areas
Clean lighting technology for killing COVID and other pathogens

Investing in People

The company designed the facility to be one of the world’s most luxurious research centers in order to deliver unrivaled study volunteer recruitment and retention. “However, the facility alone is not enough to create the optimal environment for conducting Phase I trials,” Dr. Vince continued. “The team overseeing a trial is crucial to the execution and success of any clinical study, so we carefully and thoughtfully assembled one of the most experienced early phase leadership teams in the industry so we can provide unparalleled service to our sponsors and positively change the future of clinical research.”